摘要

Background Olanzapine (OLZ) is one of the most effective atypical antipsychotics but is associated with severe metabolic side effects, in which the gut microbiota plays an important role. Akkermansia muciniphila (A. muciniphila; Akk), a Gramnegative anaerobic bacterium in the intestine, can potentially improve metabolic syndrome. @@@ Objective This study investigated the effect and underlying mechanisms of an A. muciniphila subtype (A. muciniphila(sub); Akk(sub)) on OLZ-induced metabolic dysfunction in lean and obese mice. @@@ Methods C57BL/6 female mice were fed a high-fat diet to induce obesity or normal chow for 8 weeks before OLZ treatment for 16 weeks. During the treatment period, mice in each group were orally administrated A. muciniphila(sub). Weight gain, glucose and lipid metabolism, and inflammation were evaluated. @@@ Results A. muciniphila(sub) decreased OLZ-related weight gain only at week 16 in lean mice and significantly alleviated OLZinduced hyperglycemia irrespective of diet. This was accompanied by reduced levels of glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK)-key enzymes in hepatic gluconeogenesis-and OLZ-associated insulin resistance. Moreover, OLZ-induced increases in serum interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha levels were improved by A. muciniphila(sub) in both obese and lean mice. OLZ did not increase serum lipid levels or hepatic fat accumulation. @@@ Conclusions A. muciniphila(sub) improves OLZ-related hyperglycemia via regulation of G6Pase and PEPCK levels and insulin resistance. Moreover, A. muciniphila(sub) alleviates systemic inflammation caused by OLZ. A. muciniphila(sub) is a promising probiotic treatment for OLZ-induced metabolic dysfunction.

  • 单位
    南方医科大学